JR8603 not checked

JiaRay Group

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“IV infusion on Days 1, 8, and 15 of continuous 28-day cycles”In the company’s words, NCT06783569 on ClinicalTrials.gov
Tested for
Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
Main trialPhase 1
“The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.”In the company’s words, NCT06783569 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2439 drugs for Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting May 2026 A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow JR8603

Following is part of Solo: you see every change to JR8603 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in